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ABSTRACT 
COST-BENEFIT ANALYSIS OF A DOSIMETRIC NEBULIZER USING 
CIRCULAIRE AND A TRADITIONAL VIXONE NEBULIZER 
By 
Nwakaego C. Okere, RRT 
Aerosol administration via small-volume nebulizers are still being used by selected 
patient-population. In the economic market, several nebulizer designs have become 
available, with each incorporating unique features that will potentially establish it as the 
preferred choice in aerosol delivery. With the continuous rising cost of health care 
services, clinicians are faced with the task of identifying opportunities for cost reduction 
in respiratory care. PURPOSE: The purpose of this study was to conduct a cost-benefit 
analysis of dosimetric nebulization using the Circulaire system and the traditional 
VixOne nebulizer. The desired outcome was to elevate awareness of the potential impact 
of the Circulaire, and how its adoption might reduce costs and enhance productivity in 
respiratory care. METHODS: A retrospective study using existing data collected from an 
urban tertiary adult hospital with a Level II Trauma Center was completed. DATA 
ANALYSIS: Descriptive statistics were run for each variable. The total cost of a full-time 
Registered Respiratory Therapist (RRT) with benefits per hour was calculated. The 
average number of RRTs per 12-hour shift, average number of nebulizer treatments by an 
RRT per 12-hour shift, average costs of traditional VixOne nebulizer and the Circulaire 
system were also calculated. RESULTS: Descriptive statistics indicated the annual cost 
of delivering aerosol therapy using the traditional VixOne nebulizer at 9-minutes 
treatment time to be $114,263.25 per year. The Circulaire was compared at two different 
treatment times of 5-minutes and 3-minutes, and the annual costs were $137,422.50 per 
year and $116,982.50 respectively. A sensitivity analysis was also conducted, and the 
treatment load was increased by 30%, with a reduction to 5 RRTs per shift. Data 
indicated an annual savings of 8% with the Circulaire at 5-minutes treatment time, and 
21% with the Circulaire at 3-minutes treatment time. CONCLUSION: The use of the 
Circulaire system at 5-minutes or 3-minutes treatment time can reduce department 
expenditure by reducing labor costs. 
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CHAPTER I 
Introduction 
 The rising costs of health care in the United States have become a critical issue 
that can no longer be ignored anymore. It was among the forefront of issues raised during 
the debate for reforms in the health care system. What is not widely recognized, however, 
is that this rising costs at a disturbingly rapid rate is true throughout the world, most 
especially in all developed nations (Malach and Baumol, 2010). 
 With the new millennium, consumers of health care services have felt the need to 
cut down on their coverage as a result of the rising cost of health care. However, the 
reality remains that as the demand for health care services increases, additional funding in 
this area becomes highly unlikely, and all efforts should be geared towards finding 
possible avenues for cost reduction of health care services. 
 In this era of limited health care resources, the adoption of the least expensive 
treatment modalities and the development of cost-saving medical technology will go a 
long way in minimizing the burden of health care costs. Most health care administrators, 
chief executive officers, directors, and clinicians are now veering towards several cost 
saving alternatives as means of combating the economic aspect of health care. There is a 
new focus on the economic efficiency of a strategy versus its clinical impact by weighing 
the costs against the benefits that it might bring over a number of years in the future. If 
budget gatekeepers and other key decision-makers are to be won over, proponents of the 
new product need a strategic plan to gather and present empirical evidence that 
demonstrates both clinical improvement and overall cost-effectiveness (Dunne, 2002). 
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 To facilitate the adoption of any new product, reliable and valid data are needed 
to support both the cost of the product and the benefits that are likely to arise from using 
the product. Cost-benefit analysis attempts to translate into dollar terms the improved 
clinical outcomes from a new care or treatment intervention (Dunne, 2002). The 
difference between cost-benefit analysis and cost-effectiveness analysis is that unlike 
cost-benefit analysis, cost-effectiveness analysis does not necessarily translate into a 
dollar amount. However, it compares the effectiveness of an intervention by measuring 
one or more outcomes and comparing it with the costs. 
 Just like any other sector in health care, there is also need to save costs in 
respiratory care. Most respiratory care establishments are adopting cost-effective 
modalities, aimed at saving resources for the department, improving productivity, and 
saving manpower/labor, most especially in facilities where the demand for respiratory 
therapists exceed their availability. 
 The administration of aerosol therapy via small-volume nebulizer accounts for a 
large proportion of the in-patient respiratory therapy workload in large health-care 
organizations (Hoisington, Chatburn, and Stoller, 2009). It is not uncommon to see that in 
most hospitals, the purchasing department rather than the respiratory care department 
oversee the selection of nebulizers, and the nebulizer brand selected is usually based on 
price. According to the study done by Hoisington et al. (2009), time spent delivering 
small volume nebulizer treatments accounted for approximately 40% of the clinical 
workload outside of the intensive care units. 
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 Reducing the time spent on aerosol administration can be achieved by 
modification of the nebulizer equipment to deliver aerosol more rapidly, thus shortening 
the length of treatment time. For example, if a novel nebulizer is shown to result in 35% 
fewer treatments during hospitalization, the incremental increase in the cost of the device 
should be evaluated in the context of the overall savings realized (Dunne, 2002). The 
rationale being that fewer treatments given can indirectly save cost through fewer missed 
treatments, reduced length of hospital stay, greater satisfaction by patients, and decreased 
workload on respiratory therapists ensuring that more time is spent on other important 
respiratory patient-care activities. 
 The term “nebulizer” derives from the Latin “nebula,” meaning “mist,” and 
reportedly was first used in 1872, followed by an 1874 definition as “an instrument for 
converting a liquid into fine spray, especially for medical purposes” (Rau, 2002). One of 
the oldest forms of delivering aerosol therapy is through the nebulizers. They are 
predominantly used to deliver bronchodilators to the lower respiratory tract. The liquid 
particles are converted into aerosol particles, and are deposited into the lower respiratory 
tract through inhalation. 
 Most aerosol devices do not generate a single particle size. Instead, they usually 
produce heterodisperse particle sizes. A measure used to determine a heterodisperse 
aerosol particle is the mass median diameter (MMD). The mass median diameter or mass 
median aerodynamic diameter (MMAD) indicates where the mass of drug is centered in a 
distribution of particle sizes (Gardenhire, 2008). When nebulizers are used to deliver 
medications like bronchodilators to the lungs, it is important to have the particle sizes 
within a specific range to ensure effective and better deposition into the lungs. Particle 
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sizes that are too small or too large end up being ineffective, and have no clinical benefits 
when administered. This is because particle sizes that are too small tend to be blown 
away during exhalation, thereby failing to deposit in the lung periphery, while the aerosol 
particles that are too large end up being deposited in the nose, mouth, and oropharynx. 
Aerosol particle sizes that are between 1 – 5µm usually deposit in the lower respiratory 
tract, particle sizes between 5 – 10µm mostly deposit in the upper airways, and particle 
sizes > 10µm are usually found in the nose, mouth, and oropharynx. 
 Several literatures (Dolovich et al., 2005; Hess, 2002; Rau, 2002, 2004) have 
supported the use of small-volume nebulizers because some drugs are only available for 
inhalation in liquid solutions, and also some patients who are unable to either coordinate 
their breathing, or generate a high inspiratory flow unlike with the metered-dose inhalers 
and dry powder inhalers respectively are much more comfortable using the small-volume 
nebulizers. 
 There are two main types of nebulizers. These include pneumatic nebulizers, also 
called jet nebulizers, and ultrasonic nebulizers. These nebulizers differ based on their 
principles of operation, aerosol particle size generated, and time of nebulization. The 
operation of a pneumatic nebulizer requires a pressurized gas supply as the driving force 
for liquid atomization (Hess, 2000). The solution to be aerosolized is entrained into the 
gas stream as compressed gas is delivered through a jet. The solution is then sheared into 
a liquid film which separates into droplets as a result of surface tension. A more stable 
particle size is produced by placing a baffle in the aerosol stream. The baffle acts as a 
sieve by allowing the smaller particles to pass through, preventing larger particles from 
being aerosolized, as they will fall back in the liquid reservoir.  
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 The ultrasonic nebulizer uses a piezoelectric transducer to produce ultrasonic 
waves that pass through the solution and aerosolize it at the surface of the solution (Hess, 
2000).  The piezoelectric effect is defined as the ability of some materials to convert 
electrical energy into mechanical energy which vibrates and causes the solution to be 
aerosolized. Ultrasonic nebulizers have been shown to produce particle sizes of smaller 
MMAD when compared with pneumatic nebulizers. 
 There are numerous advantages and disadvantages of using the small-volume jet 
nebulizers. Perhaps one of the greatest advantages similar with both small-volume jet 
nebulizers and ultrasonic nebulizers is the tidal breathing pattern. This is very simple and 
less complex, being the most convenient for patients who are unable to coordinate their 
breathing. Patients who are unable to generate high inspiratory flows and large volumes 
find this more effective. Another factor is also the ability to aerosolize more than one 
drug solution at a time. Jet nebulizers have the ability of modifying drug concentrations, 
allowing the delivery of higher doses.  
 In the United States, health care reimbursements are often determined by a 
number of issues. In most cases, patients tend not to use devices that they cannot afford. 
Medicare reimbursements do not cover the use of pressurized metered-dose inhalers 
(MDI) and dry powder inhalers (DPI) in non-hospitalized patients, but does for patients 
who use nebulizers in home therapy. 
 Some of the disadvantages of small-volume jet nebulizers include the length of 
time required to aerosolize, the need for an external power source, the size of the 
equipment, and its lack of portability.  Another disadvantage to the use of small-volume 
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jet nebulizers is that it increases the risk of infections. There is an increased risk of 
patient contamination when the nebulizers are not properly cleaned after use, and are 
constantly stored in wet or moist conditions. This allows for the growth of bacteria and 
other unhealthy organisms. 
 There are various factors that affect the deposition of aerosol when using the 
small-volume jet nebulizers. Some of the factors are patient-related, while others can be 
due to technical issues. Some of the patient-related factors include the breathing pattern. 
Patients are encouraged to maintain normal tidal breathing with occasional deep breaths 
for better aerosol deposition in the lung periphery. Also, with the nose acting as a filter, 
some of the aerosolized drugs are lost on patients who breathe through the nose versus 
patients who breathe through the mouth. Other patient-related factors include the degree 
of airway obstruction, artificial airway, and mechanical ventilation. 
 Several studies (Hess, 2000, 2002; Rau, 2002, 2004) have attributed the 
differences in design and nebulizer models from various manufacturers as one of the 
major technical factors affecting the deposition of aerosol when using small-volume jet 
nebulizers. Other technical factors include the density of the gas used to deliver the 
aerosol; humidity and temperature; the solution of the liquid nebulized; and the device 
interface used to deliver the aerosol. Better aerosol deposition is obtained with patients 
who are encouraged to use the mouthpiece instead of the mask. Masks that do not 
properly fit cause aerosol particles to be deposited in the face or eyes instead of their 
intended location. The amount of gas flow and pressure also affect the size of aerosol 
particle generated. Lower gas flows and pressures tend to increase particle size, while 
higher flows create a smaller particle size. The fill volume and the dead volume also 
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affect the overall performance of the nebulizers. Several studies have also reported 
greater output from pneumatic nebulizers when the fill volume is increased (Hess, 2000, 
2002; Rau, 2002, 2004). This can be explained by the fact that a greater fill volume 
increases the total output of aerosol generated, while the percentage of dead volume 
within the nebulizer increases with a small fill volume. The dead volume is the amount of 
the aerosol medication that is not delivered at the end of treatment. A fill volume of 4 – 5 
mL has been recommended. 
 With the advancements in bio-medical technology come newer and more efficient 
nebulizer designs. Jet nebulizers are predominantly classified under three major 
categories. They include constant-output nebulizers, breath-enhanced nebulizers, and 
dosimetric or breath-actuated nebulizers. Constant-output nebulizer is the type of 
nebulizer that delivers aerosol at a constant rate, without taking into account if a patient is 
inhaling or exhaling. Constant-output nebulizers are theoretically inefficient, as they (at 
least without accessory modification) result in making available for patient inhalation a 
maximum of only about one third of the total aerosol released, with the remaining two 
thirds of total aerosol output being released either during the patient exhalation or breath-
hold phase (Dennis, 1998). The traditional nebulizer cup such as the Misty-Neb with a 
mouthpiece that is connected to a T-piece is an example of the constant-output nebulizer. 
 Breath-enhanced nebulizers have designed characteristics that allow them to 
release more aerosols during patient inhalation while dropping back to residual output 
capacity during non-inspiratory phases (breath-hold and exhalation phases) (Dennis, 
1998). These devices are more superior to the constant-output nebulizers because fewer 
aerosols are lost during the non-inspiratory phases. However, a residual amount of 
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aerosol is still generated and lost to the atmosphere during the breath-hold and exhalation 
phases. Pari LC Plus and Ventstream are examples of breath-enhanced nebulizers. 
 Dosimetric nebulizers are designed to release aerosol only during the inspiratory 
phase. This can be achieved by generating aerosol only during inspiration, using a 
manual interrupter for the power-gas (as in the Pari LL) or a spring-loaded valve (as in 
the AeroEclipse) or by containing all aerosol in the device, with no release during 
expiration (as with the Circulaire) (Rau, 2002). This type of jet nebulizer design is the 
most efficient in the delivery of aerosol medications and has been shown to reduce 
treatment time and improve patient compliance (Dennis, 1998; Rau et al., 2004). 
 Specifically designed nebulizers have also been manufactured for aerosolizing 
specific medications. This is because the physical composition, efficiency, and efficacy 
of these drugs may be affected when used with regular nebulizers. Examples of such 
special nebulizer devices include the Respirgard II for the delivery of aerosolized 
pentamidine (NebuPent), Small-Particle Aerosol Generator for aerosolization of ribavirin 
(Virazole), and Pari LC which is used to aerosolize tobramycin (TOBI). Some of these 
drugs require special scavenging systems as they have also been shown to contaminate 
the environment, thereby posing a health hazard to the health care professionals. 
 In the late 1980s and early 1990s, there were reports of increased aerosol delivery 
to the lower respiratory tract when a plastic chamber was used with the nebulizer to 
capture aerosol during the expiratory phase, and provide that to the patient during 
subsequent inspiration (Hess, 2000). This concept was incorporated into the design 
system of the Circulaire (Westmed, Tucson, Arizona). The Circulaire is designed with a 
9 
 
reservoir bag of 750mL that is used to store aerosol during exhalation. On subsequent 
inhalation, stored aerosol from the bag is delivered to the patient with a one-way valve 
preventing the patient from rebreathing exhaled carbon dioxide. The Circulaire uses a 
one-way flapper valve so that gas can travel only from the direction of the aerosol storage 
bag toward the patient, thus ensuring that exhaled gas goes directly from the patient to the 
ambient environment (Piper, 2000). 
 Mason, Miller, and Small (1994) compared aerosol delivery via Circulaire system 
versus conventional small volume nebulizer. They reported an MMAD of 0.51µm, and 
concluded that the Circulaire system improved aerosol delivery to the lungs, less 
deposition in the non-targeted parts of the body, and less loss in the environment. In a 
similar study done on COPD patients, Mason and Miller (1996) also concluded that the 
Circulaire provided equal therapeutic effect with relative freedom from side effects and 
less exposure for caregivers. Hoffman and Smithline (1997) also compared Circulaire to 
conventional small volume nebulizers for the treatment of bronchospasm in the 
emergency department, and concluded that Circulaire showed greater improvement in 
bronchospasm as measured by peak flow meter. However, questions have been raised 
over the design performance of the conventional small-volume nebulizer used, as the 
Circulaire design has been shown to be of a much superior quality (Hess, 2000). 
Purpose of the Study 
 The purpose of this study was to perform a cost-benefit analysis of dosimetric 
nebulization with Circulaire and the traditional VixOne nebulizer using data 
retrospectively collected from an urban tertiary adult hospital. As clinicians, we ought to 
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be well informed about the various nebulizer designs available and purchasing decisions 
should be based on a thorough selection process. Often, the assessment of needs becomes 
the driving force for the design of the selection and evaluation process. The goal in 
purchasing a new nebulizer design is to select the nebulizer with the best performance at 
the lowest relative cost. The desired outcome of this study is to elevate awareness of the 
potential impact of this nebulizer design, and how its adoption might reduce costs and 
enhance clinical efficiency most especially in respiratory care. 
 The following research questions were addressed to guide the acquisition of data 
required to justify the purpose of this study. 
1. What was the total cost of a full-time RRT per hour? 
2. What was the average number of respiratory therapists per 12-hour shift? 
3. What was the average number of nebulizer treatments given by a respiratory 
therapist per 12- hour shift? 
4. What was the average cost of traditional VixOne nebulizer? 
5. What was the average cost of the Circulaire system? 
6. What is the average yearly cost of utilizing the VixOne nebulizer? 
7. What is the average yearly cost of utilizing the Circulaire system at a treatment 
time of 5 minutes? 
8. What is the average yearly cost of utilizing the Circulaire system at a treatment 
time of 3 minutes? 
9. Does the Circulaire system at 5 minutes reduce cost when compared to the 
VixOne nebulizer? 
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10. Does the Circulaire system at 3 minutes reduce cost when compared to the 
VixOne nebulizer? 
Significance of Study 
 The study is significant in that it might present an alternative treatment modality 
that could be least expensive and easily adopted, thereby helping to reduce the rising cost 
of health care. This study may also identify certain areas where revenue can be generated 
for the health care establishment.  
Definition of Words and Terms 
Total cost: Average cost per hour of a full-time RRT plus benefits. 
Cost-benefit analysis (CBA): Costs versus overall savings. 
Cost-effectiveness Analysis: Cost per number of cures or lives saved. 
Mass Median Aerodynamic Diameter (MMAD): The particle size above and below 
which 50% of the mass of the particles is found. 
Heterodisperse: Aerosol particles comprised of different sizes. 
Delimitations 
 This study involves retrospective data collected from an urban tertiary adult not-
for-profit hospital with a Level II Trauma Center for the year 2010. The results of this 
study can only be generalized to this health care facility. The limitation factors noted in 
this study are beyond the control of the researcher, as information gathered was done 
retrospectively. 
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Assumptions 
 The intention of this study is to prove that aerosol administration using the 
Circulaire system will save costs in a tertiary care institution, when compared to aerosol 
administration using the traditional VixOne nebulizer. This assumption is based on the 
fact that with the additional aerosol bag attached to the Circulaire system, and the one-
way expiratory valve, aerosol is effectively administered to the targeted area, and fewer 
drugs are lost to the environment at 3 and 5 minute treatment times. This will indirectly 
affect patient outcomes by reducing the length of hospital stay, thereby saving costs for 
the hospital facility. 
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CHAPTER II 
Review of Literature 
 Methods of evaluating the costs and benefits of healthcare have become 
increasingly important due to the rising costs of healthcare, and the number of economic 
evaluations of healthcare has increased dramatically (Phillips, Veenstra, VanBebber, and 
Sakowski, 2003). With ongoing inflation in the healthcare system, there is need to ensure 
that proper economic evaluation is done on all costs and benefits resulting from an 
intervention.  
 Furthermore, with the limited funds available for healthcare, as well as 
competition from other areas like education and housing, it becomes imperative that total 
funds available are allocated appropriately. Economic evaluation is defined as „the 
comparative analysis of alternative courses of action in terms of their costs and 
consequences‟ (Drummond et al., 1987; Kumar et al., 2006). However, this term is 
collectively used to describe a range of techniques that can be used to make comparison 
showing the costs, benefits, and consequences of each intervention. 
 There are several methods of economic evaluation in healthcare, and they include: 
cost-utility analysis, cost-minimization analysis, cost-effectiveness analysis, and cost-
benefit analysis. Although these methods all share some similarities, they also vary in the 
way they compare different interventions. Cost-utility analysis tends to measure benefits 
in terms of quality adjusted life years (QALY), allowing different techniques to be 
compared by standardizing the denominator. In cost-minimization analysis, interventions 
expected to have similar outcomes are assessed, and the least expensive is identified.  
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 Cost-effectiveness analysis is used for comparison when the expected outcomes 
may vary, but can be expressed as common units. While cost-benefit analysis estimates 
the total monetary value of costs and benefits of two interventions to determine which of 
them is worth the time or effort spent. Cost-effectiveness analysis and cost-benefit 
analysis in particular provide decision-makers with a framework whereby they can make 
decisions regarding healthcare provision, insurance reimbursement, and drug 
development given a fixed budget and competing choices (Phillips et al., 2003). 
 A thorough cost-benefit analysis should incorporate most of its founding 
principles. A common unit of measurement is one of the important principles of cost-
benefit analysis. In order to arrive at a conclusion as to why an intervention is best suited, 
all aspects of the intervention should be evaluated and expressed in terms of their 
equivalent monetary value; in this case, the dollar amount.  However, the most 
challenging aspect of cost-benefit analysis remains the fact that certain cost estimates are 
arbitrary by nature and as such, it becomes more difficult to obtain a true estimate of such 
costs. 
 In the course of this literature review, a systematic analysis on aerosol delivery 
and cost-saving modalities in respiratory care will be extensively discussed. It will also 
focus on cost-effectiveness and cost-benefit analysis of different nebulizer designs, 
comparing dosimetric nebulization using different nebulizer brands, and evaluating 
factors that can affect optimum aerosol delivery. 
 Resources for this review of literature were retrieved from databases such as 
Cumulative Index to Nursing and Allied Health Literature (CINAHL), the Web of 
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Science (WOS), PUBMED, Cochrane Library, and nursing and allied health 
(PROQUEST). The search terms used were “cost-benefit analysis”, “cost-benefit analysis 
in respiratory care”, and “cost-benefit analysis of dosimetric nebulization”. The articles 
reviewed spanned the last two decades, and were limited to research studies done in 
English language. These were all peer-reviewed articles, with references that are 
pertinent to the subject matter. The only setback in the course of this review was the use 
of peer-reviewed articles with greater than 10 years of publication. This can be attributed 
to the paucity of data to support this topic. 
Cost-Benefit Analysis in Respiratory Care 
 Kollef et al. (2000) carried out a single center, quasi-randomized, clinical study to 
compare the effects of respiratory care practitioner (RCP)-directed treatment protocols 
versus physician-directed orders on patient outcomes and resource utilization. The need 
for this research arose from the fact that needless respiratory therapy treatments are often 
prescribed to patients who do not derive any benefit from its administration, thereby 
wasting resources for the department. The study involved 694 consecutive hospitalized 
non-ICU patients ordered to receive respiratory treatments. The main outcomes measured 
were respiratory care charges, discordant respiratory care orders, hospital length of stay, 
and patient-specific complications. The results of the study led to the conclusion that 
RCP-directed treatment protocols were significantly cost-effective when compared to 
physician-directed orders by improving patient outcomes, and reducing the cost of 
medical care. 
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 The results of Kollef et al. (2000) were consistent with a previous study 
conducted by Stoller et al. (1998). In this randomized control trial, RCP-directed 
treatment protocols were compared to physician-directed orders, and the results 
associated RCP-directed treatment protocols with lower costs of medical care. 
 Hoisington et al. (2009) compared the respiratory care workload requirement in a 
hospital facility with a common small-volume nebulizer to that with a newer nebulizer 
design than can deliver a standard dose of bronchodilator in less time. The researchers 
hypothesized that the time saved on aerosol workload could be directed for use on other 
valued respiratory therapy patient-care activities. The respiratory care day-shift workload 
distribution in a post-thoracic-surgery ward during two consecutive 30-day periods was 
compared. For the baseline period, a standard nebulizer (VixOne, Westmed, Tucson, 
Arizona) was used, while a newer nebulizer with a higher aerosol output (NebuTech 
HDN, Salter Labs, Arvin, California) was used during the intervention period. The 
number of respiratory care procedures which have been assigned standard treatment 
times were compared during the baseline and intervention periods. The researchers 
concluded that aerosol administration time was significantly reduced with NebuTech 
HDN, and time saved was used for value-added patient-care activities. They also 
suggested that shorter treatment times may play a role in dealing with the nationwide 
shortage of respiratory therapists. 
 In 1994, LeBouef‟s study of one respiratory care department‟s contribution to the 
„bottom line‟ analyzed the financial statements of a 240-bed, not-for-profit hospital to 
determine the respiratory care department‟s actual contribution to the hospital‟s revenue 
above expenditures. In his study, he reviewed the hospital‟s profit and loss statement, the 
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respiratory care department‟s financial statement, and the financial statements for all 54 
hospital departments. His analysis revealed that the respiratory care department was the 
hospital‟s largest revenue contributor, with it generating 42.8% of the hospital‟s revenue 
above expenditures. He further suggested the need for pursuing therapist-driven protocols 
and critical pathways to become even more efficient and cost-effective in providing 
services. 
Aerosol Delivery 
 Due to costs consideration, the expense and risk associated with utilizing reusable 
devices that needs to be sterilized between patients, disposable single-patient use-
nebulizers have become the mainstay in today‟s economy. There are mass productions of 
low-cost single-patient use-nebulizers, and various factors affect the characteristics of 
these nebulizer performances. The time required for nebulization, the drug output, the 
ease of use, the costs of purchasing these nebulizers are all contributing factors that may 
affect the performances of these nebulizers.  
 Dolovich et al. (2005) conducted a systematic review of randomized controlled 
clinical trials taken from MEDLINE, EmBase, and the Cochrane Library databases to 
determine the efficacy and adverse effects of treatment using nebulizer versus pressurized 
metered-dose inhalers (MDIs) with or without a spacer/holding chamber versus dry 
powder inhalers (DPIs), as delivery systems for beta-agonists, anticholinergic agents, and 
corticosteroids.  This was done to provide recommendations for clinicians when choosing 
an aerosol delivery device. A total of 394 trials assessing inhaled corticosteroid, beta2-
agonist, and anticholinergic agents delivered by an MDI, an MDI with a spacer/holding 
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chamber, a nebulizer, or a DPI were identified for the years 1982 to 2001. A total of 254 
outcomes were tabulated. Of the 131 studies that met the eligibility criteria, only 59 
(primarily those that tested beta2-agonists) proved to have useable data. The result of the 
studies did not show any significant difference between devices in any efficacy outcome 
and in any patient group. In conclusion, the authors surmised that the basis for selecting 
an aerosol delivery device for respiratory care patients should be based on the patient‟s 
age and the ability to use the selected device correctly among other things. 
 Hess, Fisher, Williams, Pooler, and Kacmarek (1996) conducted a study to 
evaluate the effects of diluent volume, nebulizer flow, and nebulizer brand on medication 
nebulizer performance. A total of 17 nebulizers were evaluated using three different fill 
volumes, and three different oxygen flow rates. With each trial, the amount of aerosol left 
in the nebulizer and the amount deposited in the airway was measured using 
spectrophotometry. The researchers concluded that medication nebulizer function is 
affected by diluent volume, flow, and nebulizer brand and recommended that nebulizers 
should be evaluated in a setting similar to its clinical use. 
 Camargo and Kenney (2000) compiled a literature review assessing costs of 
aerosol therapy. The article introduced basic economic concepts, compared outcomes of 
beta-agonist delivery via nebulizer and MDI/spacer, and finally evaluated selected 
economic analyses of nebulizer and MDI/spacer treatment. They suggested that a useful 
way to evaluate two different interventions was to assess their cost-effectiveness, stating 
that an intervention was only cost-effective in relation to another course of action. Their 
article provided an interesting introduction to cost-benefit analysis, showed the 
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importance of critically evaluating cost analysis, and identified potential areas of 
improvement in aerosol delivery. 
Dosimetric Nebulization 
 Rau, Ari, and Restrepo (2004) performed an in vitro study to evaluate the total 
drug deposition of constant-output, breath-enhanced, and dosimetric nebulizers, using 
simulated normal adult breathing. The five nebulizer brands tested include Misty-Neb 
and SideStream (constant-output nebulizers); Pari LCD (breath-enhanced nebulizers); 
Circulaire and AeroEclipse (dosimetric nebulizers). Three of each of the five nebulizer 
brands were tested, and each device nebulized 2.5-mg unit-dose of albuterol sulfate 
solution, with a 3 mL total fill volume, powered by oxygen at 8 L/min. The outcomes 
measured were the total inhaled drug mass, exhaled/ambient drug loss, drug lost in the 
device, and drug remaining in the unit-dose bottle. Their results showed a significant 
difference in the percentage of total inhaled drug mass among all nebulizer brands tested. 
The Circulaire was approximately half that of the constant-output and breath-enhanced 
nebulizers, while the total inhaled drug mass of AeroEclipse was about 2.5 times greater. 
However, the AeroEclipse average time to sputter was over 20 minutes. The dosimetric 
nebulizers also had the least exhaled/ambient drug loss. A significant limitation to this 
study was the use of the United States Pharmacopenia (USP) throat as a simple model of 
the upper respiratory tract, instead of obtaining a measurement of particle size 
distribution and fine particle fraction. 
 A study conducted by Mason et al. (1994), suggested that the Circulaire system 
improved aerosol delivery to the lungs, reduced aerosol deposition in the body outside of 
the lungs, and showed the least ambient drug loss when compared to a conventional small 
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volume nebulizer. Based on the outcomes of their study, they suggested the replacement 
of conventional nebulizers with the Circulaire system so as to reduce the risk of 
environmental drug exposure to respiratory therapists and caregivers.  
 A follow-up study carried out by Mason et al. (1996) also supported their 
previous study. They compared aerosol delivery via Circulaire system versus a disposable 
nebulizer in chronic obstructive pulmonary disease (COPD) patients. The inclusion of 
patients having this disease process introduced abnormal physiology and the opportunity 
to evaluate therapeutic response and side effects. The study was a prospective 
randomized, crossover-controlled study comprised of 10 COPD out-patients. Their 
results showed that the Circulaire and conventional nebulizer appeared to deliver about 
the same amount of aerosol in the lungs. However, extrapulmonary deposition in the 
body and environmental contamination were significantly higher with the conventional 
nebulizers. 
 A similar study was performed by Hoffman and Smithline (1997) for the 
treatment of bronchospasm in the emergency department. The results obtained from their 
study supported previous studies on the superiority of the Circulaire system over 
conventional small-volume nebulizers. The researchers reported a greater improvement 
of bronchospasm in the Circulaire group as measured by peak flow meter. 
 Piper (2000) compared AeroTee and Circulaire, two nebulizer designs that 
incorporate the use of reservoir bags during patient exhalation with the conventional 
nebulizer T-piece with corrugated tubing. Three of each of the three nebulizer designs 
was tested with similar three VixOne nebulizers. Medication delivery rates were 
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calculated using the ratio of the inspiratory flow to the sampling flow and the total 
amount of mass collected. The result of this in vitro study was contradictory to the 
previously performed studies. The researcher found out that the AeroTee delivered 
superior performance when compared to a nebulizer T-piece with corrugated tubing. 
While the Circulaire system delivered less medication when compared to the nebulizer T-
piece with corrugated tubing. 
Conclusion 
 Regardless of the fact that MDIs and DPIs have attained much popularity as the 
preferred choice of aerosol delivery due its portability and convenience, nebulizers are 
still being used on selected patient-population. The assessment of need becomes the 
driving force for the design of the selection and evaluation process. When considering the 
purchasing of new nebulizers, focus should be on the selection of the nebulizer with the 
best performance at the lowest relative cost.  
 Research has established the need for the adoption of RCP-directed treatment 
protocols as an avenue for reducing the rising cost of medical care. It has shown that this 
treatment option is cost-effective, and improves patient outcomes. With the 
advancements in technology, techniques for aerosol delivery have not been left out. The 
introduction of dosimetric nebulization has been shown to work on selected patient-
population unable to coordinate the use of MDIs and DPIs. Direct comparisons of 
selected nebulizer brands by researchers have also established the efficiency and cost-
effectiveness of these newer nebulizer designs. Research has shown the superiority of the 
Circulaire system over the small-volume jet nebulizers and recommendations have been 
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made for its adoption in hospital facilities as it reduces the risk of environmental drug 
exposure to caregivers during aerosol delivery.  
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CHAPTER III 
Methodology 
 The study performed is a retrospective study using existing data collected from an 
urban tertiary adult hospital with a Level II Trauma Center. The objective of this study 
was to perform a cost-benefit analysis of dosimetric nebulization with the Circulaire 
system and the traditional VixOne nebulizer using data retrospectively collected .The 
data collected will be used to answer the preset research questions. 
 The analytical process involves identifying if there are monetary benefits 
associated with the use of the Circulaire system as a device for aerosol delivery, and if its 
adoption has been able to generate revenue for the respiratory care department. The 
desired outcome of this study is to elevate awareness of the potential impact of this 
nebulizer design, and how its adoption might reduce costs and enhance clinical efficiency 
most especially in respiratory care. 
Population 
 The data used for this cost-benefit analysis was retrospectively collected from the 
respiratory care department of an urban tertiary adult medical center serving Northwest 
Georgia and Northeast Alabama. The hospital is a 304-bed, not-for-profit teaching 
hospital with a full range of ancillary services and a state-designated Level II Trauma 
Center.  
 In an effort to save costs and possibly enhance the delivery of more efficient and 
effective respiratory care services, the hospital‟s respiratory care department adopted the 
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use of a new aerosol device for dosimetric nebulization. This new device is the Circulaire 
system. A cost-benefit analysis of changing aerosol devices was conducted to determine 
if the Circulaire would save resources for the respiratory care department and the hospital 
in general. Data collected for the research study was for the year 2010. 
Data Analysis 
 The data collection for this project was performed by the researcher. The 
researcher requested information from the respiratory care director of the hospital facility. 
The director supplied the data from the existing records of the respiratory care 
department for the year 2010. The researcher met with the major professor and discussed 
the key steps in conducting a cost-benefit analysis.  The models that will be used to 
assess costs, benefits/effects, and outcomes were determined. All possible variables were 
discussed and estimates for costs were developed.  
 Descriptive statistics were calculated to answer the preset research questions. For 
the purpose of this study, the Circulaire system was compared with the traditional 
VixOne nebulizer at two treatment times of 5-minutes and 3-minutes. Hoisington et al. 
(2009) in their bench observation established the standard small-volume nebulizer 
treatment time with the VixOne to be 9 minutes. Research studies on comparison of 
dosimetric nebulizers have also shown the Circulaire system to deliver the same, if not a 
greater percentage of aerosol to the airways using a lesser treatment time when compared 
to the traditional VixOne nebulizer (Gardenhire, 2011). 
 Sensitivity analysis was also performed, and certain variables where altered, with 
calculations redone so as to determine which key variables would affect the results. 
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Sensitivity analysis can be conducted by varying the assumptions about one variable and 
assessing the effect on the evaluation of the decision (one-way analysis) or by 
simultaneously allowing assumptions about multiple variables to vary and reanalyzing 
the decision (multi-way analysis) (Phillips et al., 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 
 
CHAPTER IV 
Results 
 The purpose of this study was perform a cost-benefit analysis of dosimetric 
nebulization with the Circulaire and the traditional VixOne nebulizer using existing data 
retrospectively collected from an urban tertiary adult hospital with a Level II Trauma 
Center for the year 2010. This research study explored the overall costs associated with 
the use of each nebulizer design, benefits/effects, and outcomes. 
Descriptive Data 
  The total cost of a full-time Registered Respiratory Therapist (RRT) with benefits 
per hour, average number of RRTs per 12-hour shift, average number of nebulizer 
treatments by an RRT per 12-hour shift, average costs of traditional VixOne nebulizer 
and the Circulaire system was presented in Table I.  
Table I. Average cost of variables 
Average cost per hour of a full-time RRT with benefits     $30.00 
Average number of RRTs per 12-hour shift     6.5  
Average number of nebulizer treatments by RRT per 12-hour shift     28  
Average cost of traditional VixOne nebulizer     $1.11 
Average cost of the Circulaire system     $4.30 
 
 The average cost per hour of a full-time RRT was calculated to be $24.00/hr plus 
28% for benefits making a total cost of $30.00/hr. In a 12-hour shift, an average number 
of 6.5 RRTs were required per shift, with each giving an average of 28 nebulizer 
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treatments per 12-hour shift. The average cost of a traditional VixOne nebulizer was 
$1.11, while the Circulaire was priced at $4.30. 
 Based on the information in Table I, the following calculations were made in 
Table II to estimate the annual costs of nebulizer treatment using each of the nebulizer 
designs at different treatment times. With a standard treatment time of 9 minutes for the 
traditional VixOne nebulizer, and an average cost per hour of a full-time RRT with 
benefits of $30.00, it would cost $4.50 to give a treatment. When the cost of a nebulizer 
is added to that, it amounts to $5.61 per treatment. To calculate the labor and cost of 
nebulizer treatments per RRT for a 12-hour shift, multiply $5.61 by 28 treatments to get 
$157.08. For a day (24-hour period), $157.08 is multiplied by 2 to get $314.16. Data 
collected suggests that the nebulizers where only changed as needed, thus calculations 
will be made using one nebulizer per day. The cost of the VixOne nebulizer is subtracted 
from $314.16, resulting in a total cost and labor of $313.05 per day. Therefore, the annual 
cost of delivering aerosol treatment using the traditional VixOne nebulizer would be 
$114,263.25 a year. 
 When the Circulaire is used with a treatment time of 5 minutes and an average 
cost per hour of a full-time RRT with benefits of $30.00, it would cost $2.50 to give a 
treatment. When the cost of a nebulizer is added to that, it amounts to $6.80 per 
treatment. To calculate the labor and cost of nebulizer treatments per RRT for a 12-hour 
shift, multiply $6.80 by 28 treatments to get $190.40. For a day (24-hour period), $190.40 
is multiplied by 2, and the cost of the nebulizer is subtracted to get $376.50. Therefore, 
the annual cost of delivering aerosol treatment with the Circulaire system using a 
treatment time of 5 minutes would amount to $137,422.50 a year. 
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 However, when the Circulaire is used with a treatment time of 3 minutes and an 
average cost per hour of a full-time RRT with benefits of $30.00, it would cost $1.50 to 
deliver a treatment. When the cost of a nebulizer is added to that, it amounts to $5.80 per 
treatment. To calculate the labor and cost of nebulizer treatments per RRT for a 12-hour 
shift, multiply $5.80 by 28 treatments to get $162.40. For a day (24-hour period), $162.40 
is multiplied by 2 and the cost of the nebulizer is subtracted to get $320.50. Therefore, 
the annual cost of delivering aerosol treatment with the Circulaire system using a 
treatment time of 3 minutes would amount to $116,982.50 a year. 
Table II. Annual cost of nebulizer treatment with each nebulizer design  
 
Nebulizer design and 
Treatment time 
 
VixOne 
(9 minutes) 
 
Circulaire 
(5 minutes) 
 
Circulaire 
(3 minutes) 
Cost per treatment $4.50 $2.50 $1.50 
Cost of nebulizer plus cost 
per treatment 
$5.61 $6.80 $5.80 
Cost of nebulizer treatment 
per 12-hour shift 
$157.08 $190.40 $162.40 
Cost of nebulizer treatment 
per day 
$313.05 $376.50 $320.50 
Cost of nebulizer treatment 
per year 
$114,263.25 $137,422.50 $116,982.50 
 
Sensitivity Analysis 
 I assumed an increase in treatment load by 30%, allowing a reduction to an 
average of 5 full-time RRTs per 12-hour shift. The VixOne nebulizer with 6.5 RRTs per 
12-hour shift will result in $742,711.13 annually. However, calculations cannot be made 
for 5 RRTs per 12-hour shift. Using the Circulaire at 5 minutes treatment time, an annual 
cost of $893,246.25 will be accrued with 6.5 RRTs per 12-hour shift. Whereas with 5 
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RRTs per 12-hour shift an annual cost of $687,112.50 is estimated, thus resulting in 8% 
savings. When the Circulaire is used with a treatment time of 3 minutes, and 6.5 RRTs 
per 12-hour shift, the annual cost will be $760,386.25 a year. When the number of RRTs 
per 12-hour shift is reduced to 5, an annual cost of $584,912.50 is estimated, 
consequently resulting in 21% savings. This multi-way sensitivity analysis is represented 
below in Table III.  
Table III. Multi-way sensitivity analysis  
 
Nebulizer design and 
Treatment time 
 
 
VixOne 
(9 minutes) 
 
Circulaire 
(5 minutes) 
 
Circulaire 
(3 minutes) 
6.5 RRTs per 12-hour shift $742,711.13 $893,246.25 $760,386.25 
5 RRTS per 12-hour shift ** $687,112.50 $584,912.50 
Dollar savings from VixOne **  $55598.63 $157,798.63 
Percent savings from VixOne ** 8% 21% 
Note: ** not able to calculate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
30 
 
CHAPTER V 
Discussion 
 Aerosol administration through liquid nebulization accounts for a greater 
percentage of the respiratory care workload. The administration of aerosol therapy using 
small-volume nebulizers has evolved over the years. In the economic market, different 
nebulizer designs are being manufactured, with each incorporating unique features that 
will potentially establish it as the preferred choice in aerosol delivery. There is a need to 
identify further opportunities for cost reduction in respiratory care. Most health care 
administrators, chief executive officers, directors, and clinicians are now faced with the 
tasks of deciding which of these several nebulizer designs can be used as an alternative to 
combat the rising cost of health care now at a disturbingly rapid rate.  
 The focus of this study was to perform a cost-benefit analysis of dosimetric 
nebulization with Circulaire and traditional VixOne nebulizers using data retrospectively 
collected from an urban tertiary adult hospital with a Level II Trauma Center. A cost-
benefit analysis appraises and adds up the equivalent money value of the benefits and 
costs of an intervention to determine whether it is worthwhile. However, one major 
challenge in cost-benefit analysis is that certain cost estimates, most especially indirect 
costs are, by nature, arbitrary making them more difficult to quantify.  
 As clinicians in respiratory care, we ought to be well informed about the various 
nebulizer designs available and purchasing decisions should be based on a thorough 
selection process. The desired outcome of this study was to elevate awareness of the 
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potential impact of the Circulaire system, and how its adoption might reduce costs and 
enhance clinical efficiency most especially in respiratory care. 
 In this study, data was retrospectively collected from the respiratory care 
department of an urban tertiary adult hospital with a Level II Trauma Center. The 
hospital‟s respiratory care department had recently adopted the use of the Circulaire 
system as its modality for liquid aerosol delivery, and sought to perform a cost-benefit 
analysis to determine if the Circulaire would save resources for the respiratory care 
department and the hospital in general. The costs attached to the adoption of the 
Circulaire system was compared to the traditional VixOne nebulizer being the device 
previously used by the department. The respiratory care director of the hospital facility 
supplied the data from the existing records of the respiratory care department for the year 
2010. 
 The results of the study further addressed some of the research questions that 
were previously raised. The total cost of a full-time RRT with benefits per hour, average 
number of RRTs per 12-hour shift, average number of nebulizer treatments by an RRT 
per 12-hour shift, average costs of traditional VixOne nebulizer and the Circulaire system 
were calculated and used to determine the costs, benefits, and outcomes associated with 
the use of the Circulaire and traditional VixOne nebulizer. The Circulaire was compared 
at two different treatment times of 5-minutes and 3-minutes. Research from several 
studies have shown that aerosol treatment time using dosimetric nebulizers are often 
shorter when compared to traditional constant-output nebulizers, and the dosimetric 
nebulizers have also been known to generate a higher percentage of drug deposition in 
the targeted areas (Gardenhire, 2007, 2011; Hess, 2000, 2002; Rau, 2002, 2004). With the 
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growing concerns of the Joint Commission on Accreditation of Health Care 
Organizations (JCAHO) on concurrent therapy in respiratory care, the adoption of a 
nebulizer design that allows for a shorter treatment time will potentially eliminate the 
problem of “treatment stacking” and indirectly improve the quality of patient care. In 
areas where the demand is high for RRTs, dosimetric nebulization using the Circulaire at 
3-minutes treatment time will be cost-effective and decrease the workload of the 
respiratory therapists. 
 Overall, the annual cost of delivering aerosol treatment using the Circulaire with a 
5-minute treatment time was considerably higher than the traditional VixOne nebulizer at 
a treatment time of 9-minutes. Nevertheless, it is important to note that given the length 
of treatment time, the inhaled drug mass is greater with the Circulaire at 5-minutes versus 
the VixOne at 9-minutes. Dosimetric nebulization using the Circulaire at 5-minutes and 
3-minutes treatment time can reduce department expenditure by reducing labor costs. 
This was clearly stated in the calculations made for the cost of nebulizer treatments per 
year using the different nebulizer designs at different treatment times. The time saved 
reduces labor costs, ensures fewer missed therapy, and enhances effective and skilled 
patient care. 
 When the treatment load was increased by 30%, with a reduction to an average of 
five respiratory therapists, calculations could not be made for the VixOne nebulizer. This 
is primarily because with a treatment time of 9-minutes, a reduction in the number of 
respiratory therapists per 12-hour shift will rather give room for concurrent therapy, 
increase the number of missed treatment, and potentially reduce the quality of patient 
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care. With the Circulaire at 5-minutes and 3-minutes treatment time, annual savings of 
8% and 21% were recorded. 
 Previous studies conducted on cost-benefit analysis in respiratory care were 
centered on respiratory care protocols (RCP) versus physician directed treatments as a 
means of saving costs for the respiratory care department. Kollef et al. (2000) surmised 
that RCP-directed treatment protocols were significantly cost-effective when compared to 
physician-directed orders. This conclusion was in line with a similar study carried out by 
Stoller et al. (1998) associating RCP-directed treatment protocols with lower costs of 
medical care. When Hoisington et al. (2009) compared the respiratory care workload 
requirement in a hospital facility with different nebulizer designs at different treatment 
times; they also arrived at the conclusion that shorter treatment times may play a role in 
dealing with the nationwide shortage of respiratory therapists with time saved being used 
for value-added patient-care activities. 
 The efficiency of the Circulaire system as a device for aerosol administration was 
the purpose of the study conducted by Mason et al. (1994, 1996) and it acknowledged 
better lung deposition of aerosols, with lesser amount lost in the ambient environment. In 
addition, Hoffman et al. (1997) supported the superiority of the Circulaire system over 
conventional small-volume nebulizers in the treatment of bronchospasm. 
 Significant limitations were considered in this study. Data collected suggests that 
the nebulizers where only changed as needed. This can be when the nebulizers are visibly 
soiled, or can no longer function properly. Although calculations where made with the 
assumption that a new nebulizer is used per daily treatment, we cannot clearly quantify 
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how often these nebulizers where changed. This may have an effect on the overall 
savings realized. The fewer times we use a new nebulizer for each daily treatment, the 
greater the percent savings. In reality, there will be additional savings and revenues 
generated for the respiratory care department. There was no mention if additional costs 
were incurred with training the respiratory therapists on the use of the Circulaire system. 
Lastly, another limitation to this study was that the researcher only factored in the costs 
of treatment and labor costs to arrive at an annual cost for each nebulizer design. The 
researcher was unable to calculate productivity. 
Recommendations for future research 
 Future research in the area of cost-benefit analysis using dosimetric nebulization 
should be conducted. A similar study should be conducted using existing data from more 
hospital facilities. Additional variables that will possibly address productivity and quality 
of care should be included in future research studies. Furthermore, the economic aspect 
of introducing new nebulizer designs should be thoroughly explored in a clinical setting. 
Cost-effectiveness analysis, cost-minimization analysis, and cost-utility analysis 
comparing dosimetric nebulization of aerosols are useful areas that can be delved into 
with future research studies. 
Conclusion 
 Current studies on cost-benefit analysis of dosimetric nebulization are limited and 
this study along with others should aim at saving resources for the respiratory care 
department, improving productivity, and saving manpower/labor in areas where there are 
insufficient respiratory therapists. The study should elevate awareness of the potential 
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impact of the Circulaire, and how its adoption might reduce costs and enhance 
productivity in respiratory care. According to this study, the use of the Circulaire system 
at 5-minutes or 3-minutes treatment time can reduce department expenditure by reducing 
labor costs. It is hoped that future research will be carried out to strengthen the need to 
adopt cost-reductive modalities in respiratory care. 
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